Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Single-Agent Liposomal Irinotecan Fails to Meet OS End Point in Second-Line Treatment of SCLC

August 3rd 2022

Liposomal irinotecan did not provide an overall survival benefit compared with topotecan as a second-line treatment for patients with small cell lung cancer who progressed on or after first-line platinum-based chemotherapy.

Eftilagimod Alpha/Pembrolizumab Combo Elicits Encouraging Survival Benefits in Anti–PD-1/PD-L1 Refractory NSCLC

August 2nd 2022

Eftilagimod alpha plus pembrolizumab demonstrated promising benefits in overall survival and progression-free survival as a second-line treatment in patients with non–small cell lung cancer who progressed on anti–PD-1/anti–PD-L1 therapy.

Poziotinib Elicits Encouraging Responses in EGFR Exon 20–Mutated NSCLC

August 2nd 2022

Poziotinib produced an encouraging overall response rate in patients with non–small cell lung cancer harboring EGFR exon 20 mutations, meeting the primary end point in cohort 1 of a phase 2 trial.

Subcutaneous Atezolizumab Produces Noninferior Pharmacokinetics Vs IV Atezolizumab in NSCLC

August 2nd 2022

The subcutaneous administration of atezolizumab produced non-inferior levels of the agent in the blood compared with intravenous atezolizumab in immunotherapy-naïve patients with locally advanced or metastatic non–small cell lung cancer who failed platinum-based chemotherapy.

The Impact of ADCs on Non-Small Cell Lung Cancer Treatment

August 2nd 2022

A discussion on how ADCs affect current standards of care in the non-small cell lung cancer treatment landscape.

Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

August 2nd 2022

Dr Jared Weiss presents the profile of a 70-year-old male patient with SCLC who received chemotherapy in the second line setting for discussion to the panel.

Novel Therapy for NSCLC With EGFR Exon 20 Insertion Mutation

August 2nd 2022

Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.

Is There a Role for IO Therapy in Advanced NSCLC With EGFR Mutations?

August 2nd 2022

A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.

Lurbinectedin for SCLC Treatment in the Second-Line Setting

August 2nd 2022

Dr Vivek Subbiah explains the clinical trial data that led to the approval of lurbinectedin for SCLC treatment.

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022

Dr Subbiah discusses research from the 2022 ASCO Annual Meeting, including phase 2 data (NCT04165772) in mismatch repair–deficient, locally advanced rectal cancer; findings from DESTINY-Breast04 (NCT03734029) in HER2-low unresectable and/or metastatic breast cancer; a first-in-human study (NCT04585750) in TP53-mutant advanced solid tumors; and data from LIBRETTO-001 (NCT03157128) in RET fusion–positive solid tumors.

Combinations, Ex Vivo Manipulation May Be Key to Enhancing T-Cell Activity in Lung Cancer

July 30th 2022

Roy S. Herbst, MD, PhD, discusses the importance of evaluating ways of altering tumor host factors to improve response to immunotherapy in patients with lung cancer.

Dr. Morgensztern on Advances With Amivantamab in NSCLC

July 30th 2022

Daniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw in non–small cell lung cancer.

Dr. Bazhenova on Larotrectinib and Entrectinib in NTRK Fusion–Positive NSCLC

July 30th 2022

Lyudmila A. Bazhenova, MD, discusses NTRK inhibition with larotrectinib and entrectinib in patients with NTRK fusion–positive non–small cell lung cancer.

Bispecific Antibodies and BiTEs Under Continued Evaluation in Lung Cancer

July 30th 2022

Daniel Morgensztern, MD, discusses updates on the investigation of bispecific antibodies and bispecific T-cell engagers in non–small cell lung cancer and small cell lung cancer.

Glutaminase Inhibition Represents Novel Treatment Strategy in NFE2L2- and KEAP1-Mutated NSCLC

July 30th 2022

Jonathan Wesley Riess, MD, MS, discusses a phase 1 trial examining the combination of sapanisertib and telaglenastat, and explains why glutaminase inhibition is being investigated as a novel way to treat select patients with non–small cell lung cancer.

EGFR TKI–Based Combos Could Lead to More Tailored First-Line Treatment Options in EGFR-Mutated NSCLC

July 29th 2022

Leveraging EGFR TKIs as a backbone for combination therapies will be pivotal for expanding treatment options and delivering more personalized therapies in the first-line setting for patients with non–small cell lung cancer harboring EGFR mutations.

Novel Biomarker Testing Could Enhance Immunotherapy Treatment Decisions in NSCLC

July 29th 2022

PD-L1 and tumor mutational burden are established biomarkers for leveraging immunotherapy in non–small cell lung cancer; however, their use may not be appropriate in determining treatment decisions for all patients.

Investigators Set Sights on Resistance Following Establishment of Frontline RET Inhibition in RET-Altered NSCLC

July 29th 2022

With two highly selective and active RET inhibitors approved for use in patients with metastatic RET alteration–positive non–small cell lung cancer, the dilemma is not determining which agent to select but ensuring that next-generation sequencing is done up front and in the presence of acquired resistance.

Dr. Baas on Immunotherapy in Mesothelioma Subpopulations

July 29th 2022

Paul Baas, MD, PhD, discusses the benefits of immunotherapy in subpopulations of patients with mesothelioma.

Dr. Reckamp on Treatment Decisions in MET Exon 14–Mutated NSCLC

July 29th 2022

Karen Reckamp, MD, compares capmatinib and tepotinib, 2 drugs that are approved for the treatment of MET exon 14–mutated non–small cell lung cancer.